{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:09:19Z","timestamp":1715990959388},"reference-count":26,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["CNS Oncol."],"published-print":{"date-parts":[[2014,3,31]]},"DOI":"10.2217\/cns.14.1","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T16:24:44Z","timestamp":1398702284000},"page":"109-113","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A selected review of abstracts from the 4th Quadrennial Meeting of the World Federation of Neuro-oncology"],"prefix":"10.1080","volume":"3","author":[{"given":"Marc C","family":"Chamberlain","sequence":"first","affiliation":[{"name":"Department of Neurology\/Division of Neuro-Oncology,Fred Hutchinson Cancer Research Center,University of Washington,Seattle Cancer Care Alliance,\r825 Eastlake Avenue East,POB 19023, MS G4940,Seattle,WA 98109-1023,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,4,28]]},"reference":[{"issue":"3","key":"e_1_3_2_3_1","first-page":"iii94","article-title":"Memory preservation with conformal avioidance of the hippocampus during whole brain radiotherapy (WBRT) for patients with brain metastases: preliminary results of RTOG 0933","volume":"15","author":"Gondi V","year":"2013","unstructured":"Gondi V , MehtaM, PughSet al. Memory preservation with conformal avioidance of the hippocampus during whole brain radiotherapy (WBRT) for patients with brain metastases: preliminary results of RTOG 0933. Neuro Oncol.15(Suppl. 3), iii94\u2013iii95, Abstract NC-012 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_4_1","first-page":"iii110","article-title":"Sunitinb in patients with brain metastases from metastatic renal cell carcinoma (mRCC) \u2013 final results from a global expanded access trial","volume":"15","author":"Gore M","year":"2013","unstructured":"Gore M , HariharanS, PortaCet al. Sunitinb in patients with brain metastases from metastatic renal cell carcinoma (mRCC) \u2013 final results from a global expanded access trial. Neuro Oncol.15(Suppl. 3), iii110, Abstract NO-049(2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_5_1","first-page":"iii126","article-title":"Making neoplastic meningitis diagnosable \u2013 a simple versatile powerful alternative to conventional techniques","volume":"15","author":"Patel A","year":"2013","unstructured":"Patel A , AllenJ, DickerDet al. Making neoplastic meningitis diagnosable \u2013 a simple versatile powerful alternative to conventional techniques. Neuro Oncol.15(Suppl. 3), iii126, Abstract NO-112 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_6_1","first-page":"iii102","article-title":"Rituximab concentration and effect after intrathecal administration of rituximab in CNS relapse of systemic lymphoma \u2013 results from a prospective Phase II HOVON 80 study","volume":"15","author":"Bromberg J","year":"2013","unstructured":"Bromberg J , SchoutenH, SchaafsmaRet al. Rituximab concentration and effect after intrathecal administration of rituximab in CNS relapse of systemic lymphoma \u2013 results from a prospective Phase II HOVON 80 study. Neuro Oncol.15(Suppl. 3), iii102, Abstract NO-018 (2013).","journal-title":"Neuro Oncol."},{"key":"e_1_3_2_7_1","volume-title":"4th Quadrennial Meeting of the World Federation of Neuro-Oncology.","author":"Berger MS","year":"2013","unstructured":"Berger MS . Evidence for the importance for extent of resection. Minisymposium on low grade gliomas: facts, controversies and future challenges. Presented at: 4th Quadrennial Meeting of the World Federation of Neuro-Oncology.San Francisco, CA, USA, 21\u201324 November 2013."},{"key":"e_1_3_2_8_1","volume-title":"4th Quadrennial Meeting of the World Federation of Neuro-Oncology.","author":"Brown P","year":"2013","unstructured":"Brown P . Initial results of RTOG 9802; will this be EORTC26951\/RTOG 9402 redux? Presented at: 4th Quadrennial Meeting of the World Federation of Neuro-Oncology.San Francisco, CA, USA , 21\u201324 November 2013."},{"key":"e_1_3_2_9_1","volume-title":"4th Quadrennial Meeting of the World Federation of Neuro-Oncology.","author":"Baumert B","year":"2013","unstructured":"Baumert B . The international EORTC\/NCIC-CTG\/TROG\/MRC-CTU low grade trial: temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) LGG. 4th Quadrennial Meeting of the World Federation of Neuro-Oncology.San Francisco, CA, USA, 21\u201324 November 2013."},{"key":"e_1_3_2_10_1","volume-title":"4th Quadrennial Meeting of the World Federation of Neuro-Oncology.","author":"Soffietti R","year":"2013","unstructured":"Soffietti R . Chemotherapy as initial treatment: response, monitoring and new studies. Presented at: 4th Quadrennial Meeting of the World Federation of Neuro-Oncology.San Francisco, CA, USA, 21\u201324 November 2013."},{"key":"e_1_3_2_11_1","volume-title":"4th Quadrennial Meeting of the World Federation of Neuro-Oncology.","author":"Aldape K","year":"2013","unstructured":"Aldape K . Beyond histopathology; molecular classification. Presented at: 4th Quadrennial Meeting of the World Federation of Neuro-Oncology.San Francisco, CA, USA, 21\u201324 November 2013.."},{"key":"e_1_3_2_12_1","volume-title":"4th Quadrennial Meeting of the World Federation of Neuro-Oncology.","author":"Haas-Kogan D","year":"2013","unstructured":"Haas-Kogan D . Targeting m-TOR. Aberrant signaling pathways and clinical trials for low grade glioma. Presented at: 4th Quadrennial Meeting of the World Federation of Neuro-Oncology.San Francsisco, CA, USA, 21\u201324 November 2013."},{"key":"e_1_3_2_13_1","volume-title":"4th Quadrennial Meeting of the World Federation of Neuro-Oncology.","author":"Kl Yen","year":"2013","unstructured":"Yen Kl . Targeting IDH1 mutations. Aberrant signaling pathways and clinical trials for low grade glioma. Presented at: 4th Quadrennial Meeting of the World Federation of Neuro-Oncology.San Francisco, CA, USA, 21\u201324 November 2013."},{"issue":"3","key":"e_1_3_2_14_1","first-page":"iii77","article-title":"RTOG0424: Phase II study of temozolomide (TMZ)-based chemo-radiotherapy (RT) regimen for high risk low grade gliomas (LGGs): preliminary results including quality of life (QoL) and neurological function (NCF). Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy","volume":"15","author":"Fisher B","year":"2013","unstructured":"Fisher B , ChenH, MacdonaldDet al. RTOG0424: Phase II study of temozolomide (TMZ)-based chemo-radiotherapy (RT) regimen for high risk low grade gliomas (LGGs): preliminary results including quality of life (QoL) and neurological function (NCF). Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol.15(Suppl. 3), iii77, Abstract MR-009 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_15_1","article-title":"Health Related Quality of Life results from temozolomide chemotherapy vs. radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized Phase III Intergroup study by the EORTC\/NCIC-CTG\/TROG\/MRC-CTU (EORTC22033\u201326033)","volume":"15","author":"Reijneveld JC","year":"2013","unstructured":"Reijneveld JC , BottomleyA, TaphoornMJBet al. Health Related Quality of Life results from temozolomide chemotherapy vs. radiotherapy in molecularly characterized (1p loss) low-grade glioma: a randomized Phase III Intergroup study by the EORTC\/NCIC-CTG\/TROG\/MRC-CTU (EORTC22033\u201326033). Neuro Oncol.15(Suppl. 3), Late-breaking abstract LB-004 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_16_1","first-page":"iii125","article-title":"Temozolomide followed by high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) for newly diagnosed anaplastic oligodendroglioma (AO): can radiotherapy be deferred?","volume":"15","author":"Omuro A","year":"2013","unstructured":"Omuro A , AbreyL, RaizerJet al. Temozolomide followed by high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) for newly diagnosed anaplastic oligodendroglioma (AO): can radiotherapy be deferred? Neuro Oncol. 15(Suppl. 3), iii125, Abstract NO-108 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_17_1","first-page":"iii152","article-title":"Identification of anaplastic oligodendroglioma patients benefiting from adjuvant PCV chemotherapy using the Illumina platform: a further report from EORTC 26951","volume":"15","author":"van den Bent M","year":"2013","unstructured":"van den Bent M , ErdemL, GorliaTet al. Identification of anaplastic oligodendroglioma patients benefiting from adjuvant PCV chemotherapy using the Illumina platform: a further report from EORTC 26951. Neuro Oncol.15(Suppl. 3), iii152\u2013iii153, Abstract OM-070 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_18_1","first-page":"iii105","article-title":"Final efficacy and safety results from AVAglio, a Phase III trial of bevacizumab (BEV) plus temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM)","volume":"15","author":"Chinot O","year":"2013","unstructured":"Chinot O , WickW, MasonWet al. Final efficacy and safety results from AVAglio, a Phase III trial of bevacizumab (BEV) plus temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). Neuro Oncol.15(Suppl. 3), iii105\u2013iii106, Abstract NO-031 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_19_1","first-page":"iii232","article-title":"Health related quality of life (HRQOL) analyses in the AVAglio study, a randomized, placebo controlled Phase III trial of bevacizumab, temozolomide and radiotherapy in newly diagnosed glioblastoma","volume":"15","author":"Taphoorn MJ","year":"2013","unstructured":"Taphoorn MJ , HenrikssonR, BottomleyAet al. Health related quality of life (HRQOL) analyses in the AVAglio study, a randomized, placebo controlled Phase III trial of bevacizumab, temozolomide and radiotherapy in newly diagnosed glioblastoma. Neuro Oncol.15(Suppl. 3), iii232, Abstract SM-029 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_20_1","first-page":"iii109","article-title":"RTOG 0825: primary outcome results from a Phase III randomized, placebo controlled trial evaluating bevacizumab in newly diagnosed glioblastoma","volume":"15","author":"Gilbert M","year":"2013","unstructured":"Gilbert M , PughS, WonMet al. RTOG 0825: primary outcome results from a Phase III randomized, placebo controlled trial evaluating bevacizumab in newly diagnosed glioblastoma. Neuro Oncol.15(Suppl. 3), iii109, Abstract NO-046 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_21_1","first-page":"iii226","article-title":"Comparative impact of tumor and treatment on patients reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0525","volume":"15","author":"Armstrong TS","year":"2013","unstructured":"Armstrong TS , WonM, WefelJSet al. Comparative impact of tumor and treatment on patients reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0525. Neuro Oncol.15(Suppl. 3), iii226, Abstract SM-003 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_22_1","first-page":"iii97","article-title":"Longitudinal analysis of neurocognitive outcome in patients with glioblastoma (GBM) enrolled in RTOG 0825","volume":"15","author":"Wefel JS","year":"2013","unstructured":"Wefel JS , PughS, ArmstrongTet al. Longitudinal analysis of neurocognitive outcome in patients with glioblastoma (GBM) enrolled in RTOG 0825. Neuro Oncol.15(Suppl. 3), iii97, Abstract NC-021 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_23_1","first-page":"iii77","article-title":"Bevacizumab, irinotecan and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT non-methylated glioblastoma patients: updated results from the randomized multicenter GLARIUS trial","volume":"15","author":"Herrlinger U","year":"2013","unstructured":"Herrlinger U , SchaferN, SteinbachJet al. Bevacizumab, irinotecan and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT non-methylated glioblastoma patients: updated results from the randomized multicenter GLARIUS trial. Neuro Oncol.15(Suppl. 3), iii77, Abstract MR-011 (2013).","journal-title":"Neuro Oncol."},{"issue":"3","key":"e_1_3_2_24_1","first-page":"iii80","article-title":"Cilengitide in combination with standard treatment for patients with newly diagnosed glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the open label, controlled, randomized Phase II CORE study","volume":"15","author":"Nabors LB","year":"2013","unstructured":"Nabors LB , FinkKL, MikkelsenTet al. Cilengitide in combination with standard treatment for patients with newly diagnosed glioblastoma with unmethylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the open label, controlled, randomized Phase II CORE study. Neuro Oncol.15(Suppl. 3), iii80, Abstract MR-021 (2013).","journal-title":"Neuro Oncol."},{"key":"e_1_3_2_25_1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open label, controlled, Phase 3 CENTRIC study","volume":"31","author":"Stupp R","year":"2013","unstructured":"Stupp R , HegiME, GorliaTet al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open label, controlled, Phase 3 CENTRIC study. J. Clin. Oncol.31(Suppl.), Abstract 2009 (2013).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"e_1_3_2_26_1","first-page":"iii83","article-title":"A randomized Phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB trial","volume":"15","author":"Taal W","year":"2013","unstructured":"Taal W , OosterkampH, WalenkampAet al. A randomized Phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: the Dutch BELOB trial. Neuro Oncol.15(Suppl. 3), iii83, Abstract MR-035 (2013).","journal-title":"Neuro Oncol."},{"key":"e_1_3_2_27_1","unstructured":"Bevacizumab and Lomustine for Recurrent GBM\n. www.cancer.gov\/clinicaltrials\/EORTC-26101"},{"issue":"3","key":"e_1_3_2_28_1","first-page":"iii124","article-title":"Multicenter randomized Phase II trial of methotrexate and temozolomide verss methotrexate, procarbazine, vincrisitine and cytarabine for newly diagnosed primary CNS lymphoma (PCNSL) in the elderly: an ANOCEF\/GOELAMS intergroup trial","volume":"15","author":"Omuro A","year":"2013","unstructured":"Omuro A , ChinotO, TaillandierLet al. Multicenter randomized Phase II trial of methotrexate and temozolomide verss methotrexate, procarbazine, vincrisitine and cytarabine for newly diagnosed primary CNS lymphoma (PCNSL) in the elderly: an ANOCEF\/GOELAMS intergroup trial. Neuro Oncol.15(Suppl. 3), iii124\u2013iii125, Abstract NO-107 (2013).","journal-title":"Neuro Oncol."}],"container-title":["CNS Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/cns.14.1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:55:26Z","timestamp":1715957726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/cns.14.1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,31]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3,31]]}},"alternative-id":["10.2217\/cns.14.1"],"URL":"https:\/\/doi.org\/10.2217\/cns.14.1","relation":{},"ISSN":["2045-0907","2045-0915"],"issn-type":[{"value":"2045-0907","type":"print"},{"value":"2045-0915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icns20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icns20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}